News
January 2025
Everads Leads Suprachoroidal Delivery Workshop and Delivers Corporate Presentation at the 3rd Ophthalmic Drug Delivery Summit in San Francisco
Everads Therapy’s CEO, Moshe Weinstein, led a workshop on suprachoroidal delivery, and provided a corporate update, at the 3rd Ophthalmic Drug Delivery Summit held in San Francisco Jan 28-30, 2025. Moshe also participated in a panel discussion with representatives from other players in the suprachoroidal delivery space, including Clearside, Oxular and Genentech. Including the deep dive into suprachoroidal delivery, Moshe also provided an update from Everads’ ongoing clinical trial, as well as data from the company’s internal JAK inhibitor program.
September 2024
Everads wins startup competition at the Eye and Beyond II Conference
Everads is excited to announce that it was selected as the top startup at the Eye and Beyond II conference hosted by the Ophthalmology Division of the Rabin Medical Center. The Eye & Beyond ophthalmic conference is a bi annual conference for innovation in ophthalmology. The presentation, delivered by Keren Mano Tamir, MD, Head of Scientific Strategy at Everads was recognized as the most promising ophthalmic startup for 2024.
May 2024
2 Posters at ARVO show AAV-GFP Transduction to Macular RPE and Past Posterior Pole in NHP Achieved with Everads Delivery Technology
Everads is excited to announce the presentation of two posters at ARVO 2024 featuring results in non-human primates using Everads suprachoroidal delivery technology. Eclov et al reported achieving circumferential transduction past the posterior pole using AAV2 after suprachoroidal injection in NHPs and Barak et al demonstrated the delivery of AAV5-GFP to the Macular RPE.
Access the abstracts/posters here: Eclov et al and Barak et al
May 2023
Everads’ invited to present at the 30th GoForIsrael Investment Conference.
Moshe Weinstein, CEO of Everads, presented the company at the GoForIsrael 2023 conference on May 3rd, 2023 in the innovative technologies in biotech session. This conference, in its 30th year, focuses on connecting between leading global investors and Israel’s most innovative technology companies. Organized by Cukierman & Co. and Catalyst Funds, GoforIsrael has been one of the most influential business conferences in Israel for over 25 years.
September 2022
Everads Therapy Featured at the 3rd Annual Gene Therapy for Ocular Disorders Conference
Everads Therapy announced today that Dr. Yoreh Barak, Director of Vitro-Retina Service at Rambam Medical Center, was invited to present Everads’ suprachoroidal delivery technology at the 3rd Annual Gene Therapy for Ocular Disorders conference held September 13-16th in Boston, Massachusetts.
June 2021
Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company
- Under new collaboration, partner given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties
- Agreement follows a previously-announced option deal with a global pharmaceutical company evaluating Everads' technology
March 2020
Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;
- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space.
December 2024
Overview of Clinical Data using Everads Technology Featured at Floretina2024
Clinical experience using Everads’ suprachoroidal delivery injector was presented at the Floretina2024 meeting held December 5-8. In a symposium moderated by Dr. Quan Nguyen and titled Further Progress on Suprachoroidal Delivery for Ocular Diseases, Dr. Yoreh Barak, Head of Retina at Rambam Medical Center and PI in Everads’ clinical trial, presented an overview of Everads’ technology and results from the ongoing clinical trial.
September 2024
Everads Leads Suprachoroidal Workshop at Gene Therapy for Ophthalmic Disorders Summit
Everads therapy CEO, Moshe Weinstein, and Head of Scientific Strategy, Dr. Keren Mano Tamir, co lead the suprachoroidal innovations pre-conference workshop at the 5th Annual Gene Therapy for Ophthalmic Disorders Conference in Boston. The session was co-lead by Rachel Eclov, Sr. Director, Opthalmology, of Kriya Therapeutics. The workshop provided a dead-dive into suprachoroidal delivery for gene therapy, including a review of suprachoroidal delivery and various delivery technologies, preclinical considerations for device and capsid and clinical updates from Everads first in human clinical trial.
September 2023
Everads enters license agreement with Kriya Therapeutics for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology.
For Kriya's press release click here
For Everads' press release click here
July 2022
Everads Therapy announced today that Israel’s Innovation Authority (IIA) has awarded a grant to help fund the company’s research and development. Moshe Weinstein, Everads’ CEO, stated that “We are excited to have been awarded this competitive grant, the receipt of which is a validation of the strong business and scientific case for our technology and pipeline. The grant programs of the Israel Innovation Authority are a true catalyst for Israeli companies, and we are honored and humbled to have been chosen.”
August 2020
Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets.
While granting the pharma company exclusivity for specific ocular targets, Everads has retained the right to work on other targets and treatments, both independently and with other partners.
November 2024
Everads Suprachoroidal Delivery Featured at OIS XIV Conference
Everads’ suprachoroidal delivery platform was presented at the Ophthalmology Innovation Source (OIS) 14th annual conference held in San Diego on November 22-23rd (ois.net/ois-xiv/). As part of a panel session titled “Spotlight on Suprachoroidal Drug Delivery”, Moshe Weinstein, Everads CEO, shared recent updates from the company’s ongoing clinical trial, as well as provided an overview of Everads’ internal and license-partner pipeline.
September 2024
Everads Presents Clinical Data from First-in-Human Trial of Suprachoroidal Delivery Technology at EURETINA
Presentation: Everads Therapy
June 2023
Everads is pleased to announce the publication in Translation Vision Sciences & Technology (TVST), an ARVO journal, of data showing that Everads’ suprachoroidal delivery technology enables safe, rapid and broad delivery throughout the posterior pole in non-human primate models. This work demonstrated that Everads’ technology was able to deliver 150-200 µL of ICG dye to the back of the eye via the suprachoroidal space. The injection was well tolerated in NHP eyes, with rapid distribution into the macular region and throughout the posterior pole. Moshe Weinstein, CEO of Everads, stated that “we are honored to have such a prestigious journal publish this promising data. Demonstrating the efficacy of this technology in non-human primates further confirms the promising results that can be achieved with our technology and we look forward to continuing its development with our collaborators”.
